Mainstream

Exelixis outlines continued cabozantinib growth and zanzalintinib pipeline acceleration as new launches drive 19% revenue increase

Exelixis outlines continued cabozantinib growth and zanzalintinib pipeline acceleration as new launches drive 19% revenue increase

Post ContentexelRead More

You might also be interested in reading White House: Stablecoin Yield Ban Costs More Than It Saves.

July 29, 2025
In Mainstream